Posted on

Where We Left Off: Closing Out Antioxidants and Opening Cardiovascular Health

Wray, Georgia, evening light over the lake. Some weeks get away from you. The vine keeps growing regardless.

We missed a couple of weeks in this series. My son got married, and that took priority over the publishing calendar — no apology needed for that trade, and I’d make it again.

Rather than backfill two posts that have already lost their moment, we’re picking up the series where it matters most: closing out June’s antioxidant theme with the piece that ties it together and opening July with what’s next. If you want the OPC and ellagic acid stack content or the deeper estate-sourcing piece we’d originally planned for mid-June, reach out — we’re happy to send that material directly.

Closing Out Antioxidants: The Sourcing Argument

Everything we covered this month came back to the same point: a defensible antioxidant formula needs a mechanistic story, not just an ORAC number. Ellagic acid, OPCs, resveratrol, and anthocyanins — the muscadine phytochemical profile — connect to documented oxidative stress pathways in published research, including UV-relevant mechanisms studied in human skin cell models.

The sourcing side of that story is just as important as the science. Muscadine Seed Extract and Extract Powder come from Paulk Vineyards, the growing operation — 800+ acres in Wray, Georgia, seventh generation on the farm, fourth generation with muscadines. Muscadine Products Corporation processes everything on-site. No brokers between the vine and the ingredient lot. When a formulator builds a claim on a specific mechanism and a traceable source, that claim holds up in a way a generic antioxidant blend usually doesn’t.

That’s where we left it.

Opening Cardiovascular: Starting With Honest Research

Cardiovascular health is one of the most scrutinized categories in the supplement industry, and it deserves that scrutiny. Claims in this space are held to the real clinical literature more often than in almost any other category because the stakes for consumers are higher.

The most directly relevant published human research on muscadine and cardiovascular outcomes is the Mellen et al. study (Journal of the American College of Nutrition, 2010). It’s worth knowing exactly what that study found before we go further into July, because we’re not going to build this month’s content on a study we haven’t represented accurately.

Here’s the honest summary: 50 adults with coronary disease or at least one cardiac risk factor received 1,300 mg of muscadine grape seed supplement daily or placebo for four weeks each in a randomized, double-blind, crossover design. The primary outcome — flow-mediated dilation, a measure of endothelial function — did not show a statistically significant improvement. There was a significant increase in resting brachial artery diameter with muscadine grape seed supplementation, but the study authors explicitly stated that the clinical significance of this finding has not yet been established.

  • Primary endpoint (FMD): not statistically significant
  • Secondary finding (resting brachial diameter): statistically significant increase; clinical significance not established
  • No significant changes in biomarkers of inflammation, lipid peroxidation, or antioxidant capacity
  • Study authors’ conclusion: more research is needed to fully characterize the vascular effects of muscadine and other grape-derived supplements and to determine whether those effects translate into clinical benefit

We’re telling you this upfront because it’s the responsible way to open a month built around cardiovascular claims — and because a cardiovascular ingredient story built on a misread study is the kind of thing that falls apart the moment a retailer’s science team or a practitioner asks a follow-up question. The study does not support a cardiovascular benefit claim for muscadine grape seed supplementation. (These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.) What it does establish is that muscadine grape seed has been studied in a real, peer-reviewed, randomized trial in a cardiovascular risk population. That puts it in different territory than most botanical ingredients marketed for heart health. Most of those have no human trial data to back them up at all.

Over the next few weeks, we’ll delve deeper into that study, the broader polyphenol-vascular research landscape, and how a formulator should approach positioning an ingredient with this kind of research profile — real, peer-reviewed, and not yet conclusive.

If you want the full Mellen study citation and methodology to start that conversation with your R&D team, reach out at muscadineproducts.com.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The Mellen et al. (2010) study examined muscadine grape seed supplementation in subjects with coronary disease or cardiac risk factors; the primary outcome measure did not reach statistical significance, and the clinical significance of the secondary finding has not been established. This research does not constitute evidence of a cardiovascular health benefit. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products.   Muscadine Products Corporation  •  Wray, Georgia  •  muscadineproducts.com

Posted on

What the Banini Study Actually Shows — and What It Doesn’t

muscaidne vine close up in late spring

Last week, we made a commitment: to tell you what the research on muscadine actually shows, including where it stops. This week, we’re following through.

The Banini study is the most directly relevant published human trial on muscadine and metabolic markers. Here’s exactly what it was, what it found, and where its limits lie.

The Study at a Glance

Banini AE, Boyd LC, Allen JC, Allen HG, and Sauls DL. “Muscadine grape products intake, diet and blood constituents of non-diabetic and type 2 diabetic subjects.” Nutrition, 2006; 22(11–12):1137–1145. North Carolina State University.

ElementDetail
StudyBanini AE et al., Nutrition 2006; 22(11–12):1137–1145
InstitutionNorth Carolina State University, Raleigh, NC
DesignNon-randomized, non-blinded dietary intervention; 28 days
PopulationType 2 diabetic subjects (assigned to MJ, MW, or Dz-W) and non-diabetic subjects (juice only)
Intervention150 mL/day of muscadine grape juice (MJ), muscadine grape wine (MW), or dealcoholized muscadine grape wine (Dz-W) with meals
Primary outcomesGlycemic indices, blood glucose, insulin, glycated hemoglobin (HbA1c), lipid profile, blood constituents
Key findingsDiabetics given MW and Dz-W showed lower blood glucose, insulin, and HbA1c vs. diabetics given MJ. Dz-W group: fasting blood insulin reduced; glucose:insulin ratio improved from 8.5 to 13.1. MJ and MW did not differ in fasting glucose, insulin, or HbA1c in the non-diabetic group.
Study limitationNon-diabetic group received juice only — no wine or Dz-W arm. No placebo control. Cannot compare non-diabetic outcomes to diabetic outcomes across product types.

What It Found

The most meaningful findings came from Type 2 diabetic subjects assigned to muscadine wine and dealcoholized muscadine wine. Compared with diabetics given muscadine juice, those groups had lower blood glucose, insulin, and glycated hemoglobin levels over the 28-day period.

The dealcoholized wine group — the arm most relevant to a supplement context, since alcohol is removed — showed a specific improvement in fasting blood insulin levels. The fasting blood glucose-to-insulin ratio rose from 8.5 to 13.1 over the intervention period. The researchers noted that a ratio below 7 is considered predictive of insulin resistance; the published data showed movement away from that threshold in the T2D group over 28 days.

These are real findings from a real peer-reviewed study in a population where metabolic markers matter most.

What It Doesn’t Show

Here is where we’re going to be direct, because this is where ingredient marketing most often goes wrong.

The non-diabetic subjects in this study received only muscadine juice. There was no wine or dealcoholized wine arm for healthy subjects, and no placebo control for that group. You cannot draw conclusions about muscadine’s effect on healthy adults’ metabolic markers from this study design.

The intervention used whole beverage forms — 150 mL of juice, wine, or dealcoholized wine per day. This is not the same as a standardized extract powder or capsule. The polyphenol dose, bioavailability, and matrix context of a beverage differ from those of an encapsulated ingredient. Extrapolating these findings to a capsule product requires additional research.

28 days is a short intervention window. These findings are a signal worth taking seriously, not a conclusion about long-term metabolic outcomes.

This was not a randomized, blinded, placebo-controlled trial — the design most likely to produce generalizable results. The findings are meaningful and peer-reviewed, but the study design has limitations that should inform how confidently you cite it.

Why This Still Matters for Formulators

Here’s why it still matters.

Many metabolic health ingredients have limited or no peer-reviewed human research. Their evidence base often rests on mechanistic rationale — in vitro studies showing that a compound interacts with a relevant pathway in cell culture, which is a long way from a human outcome. The Banini study, with its clearly stated limitations, still places muscadine in a category most competing ingredients cannot enter.

This research also holds up when a retailer or practitioner asks the right question — not “what does your marketing say?” but “what does your best published human study actually show?” We can answer that with a citation, a methodology, and an honest account of what was and wasn’t found. That’s a more defensible position than most suppliers in this category can offer.

The Right Application

Given what this study used, the MPC ingredient form most directly relevant to this research context is Muscadine Juice Concentrate — the beverage-form polyphenol delivery that most closely mirrors what was studied. It is appropriate for liquid supplement applications and functional beverage formulations.

Muscadine Skin/Seed Powder — our encapsulated ingredient form — provides the same phytochemical profile in capsule or tablet applications. It is a non-soluble powder, appropriate for encapsulation, not for beverage blending. The phytochemical case for that form is strong; the direct clinical link to the Banini study is more attenuated, and we will not overstate it.

If your R&D team wants to review the full Banini citation, methodology, and published abstract, contact us and we’ll send them directly. We’d rather put the actual study in front of your team than a polished summary.

Next Week

The series moves to June’s theme: Skin Health / Beauty From Within. We’ll cover Muscadine Seed Oil and Skin Extract — two ingredients with a genuinely differentiated story for cosmetic formulators and ingestible beauty brands. If you want to be ready for that conversation, visit muscadineproducts.com to request a sample or technical documentation.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Research references are cited for informational and educational purposes. The Banini study was conducted in a Type 2 diabetic population using whole beverage forms of muscadine; findings should not be generalized to healthy populations or encapsulated ingredient forms without additional research. Formulators should consult qualified regulatory counsel before establishing label claims for finished consumer products.   Muscadine Products Corporation  •  Wray, Georgia  •  muscadineproducts.com